Can-Fite BioPharma Ltd.CANFNYSE
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank43
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P43
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2024 | -3.78% |
| 2023 | -22.93% |
| 2022 | -21.19% |
| 2021 | -17.58% |
| 2020 | 8.88% |
| 2019 | 80.67% |
| 2018 | 15.24% |
| 2017 | -13.27% |
| 2016 | 57.63% |
| 2015 | -7.32% |